Bertrand Delsuc on Twitter: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / Twitter
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Mim8 does not affect FVIII function in hemophilia A - ISTH Congress Abstracts
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
Novo Nordisk's hemophilia drug shows potential as once-monthly treatment — MedWatch
Novo Nordisk to buyout Emisphere Technologies for $1.8B (NYSE:NVO) | Seeking Alpha
A multiple ascending dose study of Mim8 in patients with severe haemophilia A with or without factor VIII inhibitors
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood - ISTH Congress Abstracts
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
Hemophilia Clinical Research Trials | CenterWatch
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX - ISTH Congress Abstracts
Novo makes a rare disease push | Evaluate
%20for%20Hemophilia.png?md=1 "NNC0365-3769 (Mim8) for Hemophilia Clinical Trial 2023 | Power")
NNC0365-3769 (Mim8) for Hemophilia Clinical Trial 2023 | Power
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 clinical development program: an overview of the FRONTIER studies
Study Set to Assess Mim8 Therapy in People With Hemophilia A
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors - ISTH Congress Abstracts
A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys - Lauritzen - 2022 - Journal of Thrombosis and
Novo Nordisk gets CDSCO Panel nod to study NN0365-3769
